Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
Mitchell R. Smith, Karim Fizazi(Institut Gustave Roussy), Arun Balakumaran(Allogene Therapeutics (United States)), Robert E. Coleman(Weston Park Cancer Centre), K. Pittman(Queen Elizabeth Hospital), Piotr Milecki(Poznan University of Medical Sciences), Laurence Klotz, H. Wang(Amgen (United States)), K.N. Chi(BC Cancer Agency), Ada Braun(Amgen (United States)), Siobhan Ng(St John of God Subiaco Hospital), R. Wei(Amgen (United States))
Cited by 145
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k